RCT | Long-term survival benefit with abiraterone plus ADT in metastatic PC, but no advantage with enzalutamide association

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol – The Lancet Oncology

Commentary on Twitter

NEW: Final results from two randomised ph 3 trials of the STAMPEDE platform protocol suggest that enzalutamide and abiraterone should not be combined for patients with prostate cancer starting long-term androgen deprivation therapy. #pcsmhttps://t.co/P1uqzE4Wsv pic.twitter.com/l8U7DQZIoe

— The Lancet Oncology (@TheLancetOncol) May 4, 2023